Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis

Matsuoka, Katsuyoshi; Togo, Kanae; Yoshii, Noritoshi; Hoshi, Masato; Arai, Sadahiko

doi:10.5217/ir.2021.00154

Cited by 8 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 29 30 Furthermore, a recent study has reported that patients with UC who were administered calcineurin inhibitors had higher incidence rate of infections requiring hospitalization, herpes zoster, and malignancies than those not administered these therapies. 31 However, most patients in this study received tacrolimus, followed by tacrolimus and mycophenolate mofetil, as immunosuppressive agents after transplantation. No association with safety or prognosis was observed in patients with IBD after transplantation.…”

Section: Discussionmentioning

confidence: 97%

Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

Kim,

Kim

et al. 2024

Yonsei Med J

View full text Add to dashboard Cite

Purpose This study aimed to evaluate the safety of biologics and small molecules for the treatment of inflammatory bowel diseases (IBD) in patients receiving antirejection therapies after organ transplants. Materials and Methods We reviewed the medical records of patients with IBD who received organ transplants at the Asan Medical Center between January 1989 and December 2021. We compared the parameters of patients receiving biologics or small molecules to those of patients without those therapies. Results This study included a total of 53 patients (ulcerative colitis, 41; Crohn’s disease, 6; and gastrointestinal Behçet’s disease, 6). Among them, 15 patients were receiving biologics or small molecules and 38 were not. During a mean follow-up of 119 months, the proportion of patients experiencing severe infections was significantly higher in those treated with biologics or small molecules than in those not treated. However, other safety outcomes (e.g., malignancies, adverse events, including organizing pneumonia or hepatic failure, and death) were not different between the two groups. Kaplan–Meier curve analysis revealed no significant difference in the safety outcome rate related to the use of biologics or small molecules. During follow-up, eight patients underwent bowel resections for IBD. The rate of bowel resection was not different between the two groups. Conclusion The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.

show abstract

Section: Discussionmentioning

confidence: 97%

Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

Kim,

Kim

et al. 2024

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…The claims-based algorithms, developed with expert input, identified cohorts of patients with demographics and clinical characteristics as expected for these infectious diseases. Other retrospective claims database studies in Japan used algorithms with ICD-10 diagnosis codes only [ 21 ], or ICD-10 diagnosis codes plus claims data regarding prescription medication [ 2 , 22 ]. These studies did not validate the algorithms using clinical information.…”

Section: Discussionmentioning

confidence: 99%

Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan

Hase,

Suzuki,

de Luise

et al. 2023

BMC Infect Dis

View full text Add to dashboard Cite

Background To validate Japanese claims-based disease-identifying algorithms for herpes zoster (HZ), Mycobacterium tuberculosis (MTB), nontuberculous mycobacteria infections (NTM), and Pneumocystis jirovecii pneumonia (PJP). Methods VALIDATE-J, a multicenter, cross-sectional, retrospective study, reviewed the administrative claims data and medical records from two Japanese hospitals. Claims-based algorithms were developed by experts to identify HZ, MTB, NTM, and PJP cases among patients treated 2012–2016. Diagnosis was confirmed with three gold standard definitions; positive predictive values (PPVs) were calculated for prevalent (regardless of baseline disease-free period) and incident (preceded by a 12-month disease-free period for the target conditions) cases. Results Of patients identified using claims-based algorithms, a random sample of 377 cases was included: HZ (n = 95 [55 incident cases]); MTB (n = 100 [58]); NTM (n = 82 [50]); and PJP (n = 100 [84]). PPVs ranged from 67.4–70.5% (HZ), 67.0–90.0% (MTB), 18.3–63.4% (NTM), and 20.0–45.0% (PJP) for prevalent cases, and 69.1–70.9% (HZ), 58.6–87.9% (MTB), 10.0–56.0% (NTM), and 22.6–51.2% (PJP) for incident cases, across definitions. Adding treatment to the algorithms increased PPVs for HZ, with a small increase observed for prevalent cases of NTM. Conclusions VALIDATE-J demonstrated moderate to high PPVs for disease-identifying algorithms for HZ and MTB using Japanese claims data.

show abstract

“…The data contains routinely collected information on the following items for patients with COVID-19 until December 31, 2021: age; sex; diagnoses based on the International Classi cation of Diseases Tenth Revision (ICD-10) codes [18]; daily medical procedures and medications; discharge summary including body weight, height, and date of hospital admission and discharge; and survival status. There have been many clinical studies for COVID-19 or infectious diseases in recent years using data from MDV [19][20][21]. We described several demographic characteristics of patients with COVID-19 from MDV data compared with those from publicly available data for COVID-19 by the Japanese Ministry of Health, Labor and Welfare (MHLW) [22] (Supplementary Fig.…”

Section: Study Design and Data Sourcementioning

confidence: 99%

Incidence and Potential Risk Factors of Human Cytomegalovirus Infection in Patients with Severe and Critical COVID-19: A retrospective cohort study

Imoto¹,

Imai²,

Kawai³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Human cytomegalovirus (HCMV) reactivation occurs in immunosuppressed individuals and is known to increase mortality. Although patients with coronavirus disease 2019 (COVID-19) are often associated with steroid use and intensive care unit (ICU) treatment and may be at risk for comorbid HCMV reactivation, there are still insufficient studies. This study aimed to examine the incidence and potential risk factors of HCMV infection in patients with severe COVID-19 and evaluate the relationship between HCMV infection and mortality. Methods We used administrative claims data from advanced treatment hospitals in Japan to identify and analyze patients with severe or critical COVID-19. We explored potential risk factors for HCMV infection using multivariable regression models and its contribution to mortality in patients with COVID-19. Results Overall, 33,151 patients who progressed to severe or critical COVID-19 illness were identified. The incidence of HCMV infection was 0.3–1.7%. Steroids, immunosuppressants, ICU admission, and blood transfusion were strongly associated with HCMV reactivation. Furthermore, HCMV reactivation was associated with patient mortality independent of the observed risk factors for death. Conclusions HCMV infection is a notable complication in patients with COVID-19 receiving steroids, immunosuppressants, ICU admission, and blood transfusion, and it can significantly increase mortality risk.

show abstract

Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis

Cited by 8 publications

References 36 publications

Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan

Incidence and Potential Risk Factors of Human Cytomegalovirus Infection in Patients with Severe and Critical COVID-19: A retrospective cohort study

Contact Info

Product

Resources

About